Barely Significant
← all phrases

“nominally significant”

7,733 sentences · 7,733 papers · 10,034 search hits before verification · confirmed specimen

Sighted at

p=0.08

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

nominally significantp = 0.0050.1× alphagold
Power to establish whether a variant is a risk factor or not is low as there were only 1774 AA cases and accordingly only R161H in SDF2L1 was even nominally significant ( p = 0.005) in AA, yet all 8 risk alleles with European MAF > 0.01 are concordant in their observed direction of effect in AA and EA (contrast the heights of the dark and lighter-blue shades for AA, or dark and lighter reds for the two EA cohorts in Fig. 1 ).
nominally significantP = 0.00500.1× alphagold
In the Results, in the “Part B cohort with infantile-onset SMA: neurodegeneration” section, the text “...compared with the ENDEAR matched sham group (30% reduction)” has been corrected to “...compared with the ENDEAR matched sham group (32% reduction)”, and “nominally significant P = 0.0050” has been corrected to “nominally significant P = 0.0075”.
nominally significantP = 0.005130.1× alphagold
Similarly, scores constructed from Latino GWAS results ( P T ≤ 0.5) were of greatest predictive value among Latinos (liability R 2 = 2%; P = 3.11 × 10 −19 ) and Europeans (liability R 2 = 0.8%; P = 1.60 × 10 −9 ); with scores based on P T ≤ 0.05 and pairwise r 2 < 0.1 showing nominally significant association with case-control status among African ancestry individuals (liability R 2 = 0.2%; P = 0.00513).
nominally significantP = 5.18E−030.1× alphagold
The proportion of heritability of persistent ADHD attributable to common single-nucleotide polymorphisms on the liability scale (SNP- h 2 ) was 0.19 (SE = 0.024), with a nominally significant enrichment in the heritability of variants located in conserved genomic regions ( P = 5.18E−03) and in the cell-specific histone mark H3K4me1 ( P = 3.17E−02) (Fig.
nominally significantP = 0.00530.1× alphagold
Iptacopan improved the eGFR slope by +10.7 mL/min/1.73 m 2 /year compared with pretreatment decline ( P = 0.0057) and also led to a nominally significant reduction in glomerular C3 deposition (mean difference: –1.875; P = 0.0053). 66 In a study evaluating early access use of iptacopan (200 mg twice daily) in 16 patients with recurrent C3G after kidney transplantation, iptacopan was associated with potential stabilization of kidney function.
nominally significantP = 0.00540.1× alphagold
1SMR analysis identified four nominally significant associations, including genetically predicted Cer(d39:1) with higher levels of ALT (β = 0.39; 95% CI = 0.11, 0.66; P = 0.0054), and AST (β = 0.32; 95% CI = 0.03, 0.60; P = 0.028), SM(d33:1) with higher HbA1c (β = 0.39; 95% CI = 0.12, 0.65; P = 0.0042), and PC(40:8) with lower bilirubin (β = −0.28; 95% CI = −0.55, −0.01; P = 0.044) ( Fig. 4 a, Supplementary Table S11 ).
nominally significantp = 5.83 × 10 −30.1× alphagold
We found nominally significant subcortical volumetric differences in the bilateral thalami (left Cohen d = −0.29, p = 5.83 × 10 −3 ; right d = −0.24, p = 0.025), bilateral hippocampi (left d = −0.36, p = 8.85 × 10 −4 ; right d = −0.41, p = 1.15 × 10 −4 ), bilateral amygdalae (left d = −0.31, p = 4.02 × 10 −3 ; right d = −0.17, p = 0.014) and right nucleus accumbens ( d = −0.21, p = 0.048) between the patients with schizophrenia and controls ( Figure 2A and Figure 3 ).
nominally significantp = 0.00590.1× alphagold
ii) Nominally significant differences were observed in the levels of IL-1RA (p = 0.0059), YKL40 (p = 0.0069), CatS (p = 0.013), sTNFR1 (p = 0.031), and BDNF (p = 0.020), where these factors exhibited higher plasma levels in Cannabis user SCZ patients than in non-users. iii) These differences in systemic levels were not reflected by altered mRNA expression of genes encoding sgp130, IL-1RA, YKL40, CatS, sTNFR1, and BDNF in whole blood.
nominally significantp = 0.0060.1× alphagold
We observed several complex interactions, notably suggesting an increased risk of severe neutropenia in patients carrying a homozygous variant CYP3A5 rs776746 genotype (nominally significant OR 5.58, p = 0.006) and a potential pleiotropic protective effect from NFATC2 rs6021191 (OR 0.09, p = 0.001).